Breast Cancer Recurrence
Mostrando 25-36 de 74 artigos, teses e dissertações.
-
25. Detecção e correlação prognostica da ciclina/PCNA na detecção do carcinoma mamario
Invasive breast carcinoma of 68 patients were stúdied for the presence of Proliferative Celular Nucleous Antigen - cyclinlPCNA by immunoperoxidase method. The results of semiquantitative analysis were correlacioned with axillary status, histologic and nuclear grade and estrogen receptors attempts to identify the importance of this protein as a new prognosti
Publicado em: 1993
-
26. Tratamento conservador do carcinoma mamario : estadios I e II
From 1981 to 1988, 265 patients with breast cancer stages I and II (UICC-1987), were evaluated after conservative treatment with quadrantectomy plus axillectomy, radiotherapy and chemotherapy. After surgical treatment, the patients were submitted to radiation therapy in the breast, receiving megavoltage with cobalt-60 or 4 Me V linear accelerator and a total
Publicado em: 1990
-
27. Estudo clinico sobre a importancia do receptor de estrogeno no carcinoma mamario
Invasive breast carcinoma of 501 patients were studied for the presence and quantity of estrogen receptors, through the biochemical method of dextran charcol coated (DCC). Patients were analysed clinically regarding staging, adjuvant treatment, relapse, response of recurrence to treatment, treatment of advanced cases and inflammatory carcinoma. There was a g
Publicado em: 1990
-
28. Surgical adjuvant treatment of locally advanced breast cancer.
The reported incidence of local recurrence after mastectomy for locally advanced breast cancer (TNM Stage III and IV) is between 30% and 50%. The purpose of this study was to evaluate the effect of radiation therapy (XRT) followed by total mastectomy on the incidence of local recurrence in patients with locally advanced breast cancer. Fifty-three patients wh
-
29. Long-term results of breast conservation therapy for breast cancer.
OBJECTIVE: This study was done to determine the long-term outcome of breast conservation therapy (BCT) for patients with early-stage breast cancer during a period of treatment evolution at a single institution. SUMMARY BACKGROUND DATA: Breast cancer treatment has evolved from extensive surgical extirpation of the breast to treatment options that conserve the
-
30. A multigene RT-PCR assay used to predict recurrence in early breast cancer: two presentations with contradictory results
During the 2003 San Antonio Breast Cancer Symposium two studies were presented that were designed to validate a recurrence score, derived from a 21-gene RT-PCR assay, in patients with axillary node-negative breast cancer. This recurrence score was highly predictive for the risk of recurrence in 668 patients treated in a large multicenter trial with adjuvant
BioMed Central.
-
31. New therapeutic possibilities in primary invasive breast cancer.
OBJECTIVE: Current therapy for small invasive breast cancer, particularly when discovered mammographically, was re-examined. Axillary dissection may be avoided when lymph node metastases incidence is low (< 10%) or when primary cancer features determine adjuvant therapy. Radiation therapy may be avoided when risk of recurrence is very low. SUMMARY BACKGROUND
-
32. Referral, Receipt, and Completion of Chemotherapy in Patients With Early-Stage Breast Cancer Older Than 65 Years and at High Risk of Breast Cancer Recurrence
American Society of Clinical Oncology.
-
33. Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer
American Society of Clinical Oncology.
-
34. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value.
Human cancer cells with a mutated p53 tumor-suppressor gene have a selective growth advantage and may exhibit resistance to ionizing radiation and certain chemotherapeutic agents. To examine the prognostic value of mutations in the p53 gene, a cohort of 90 Midwestern Caucasian breast cancer patients were analyzed with methodology that detects virtually 100%
-
35. An Absence of Stromal Caveolin-1 Expression Predicts Early Tumor Recurrence and Poor Clinical Outcome in Human Breast Cancers
Previously, we showed that caveolin-1 (Cav-1) expression is down-regulated in human breast cancer-associated fibroblasts. However, it remains unknown whether loss of Cav-1 occurs in the breast tumor stroma in vivo. Here, we immunostained a well-annotated breast cancer tissue microarray with antibodies against Cav-1 and scored its stromal expression. An absen
American Society for Investigative Pathology.
-
36. Aromatase inhibitor cuts risk of recurrence of breast cancer
BMJ Publishing Group Ltd..